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In rodents calorie restriction (CR) reduces cancer incid-
ence, improves health by delaying age-related declines
in physiologic measures, and extends both median and
maximal life span. The mechanisms underlying the
various beneficial effects of CR remain undefined. In this
study, heterozygous p53-deficient (p53F/–) mice (in which
the inactivation of one allele of the p53 tumor suppressor
gene increases susceptibility to spontaneous and carcino-
gen-induced tumor development) and wild-type (WT)
litter mates were subjected to a two-stage skin carcino-
genesis protocol with 7,12-dimethylbenz[a]anthracene
and 12-O-tetradecanoylphorbol-13-acetate. Instead of
skin carcinomas, however, the chemical treatment proto-
col caused ulcerous skin lesions, and 89% of mice fed ad
libitum died from infection/septicemia. When WT mice
Calorie restriction (CR) is acknowledged to be the mosteffective dietary manipulation available for prolonginglife span and improving health in rodents, and is in factthe only intervention that consistently extends bothmedian and maximal life span in mammals (Roth et al,
1995). CR (in practice, the reduction of calorie intake without
malnutrition) has been shown to affect hundreds of physiologic
parameters, including immune responses, gene expression, rates of
protein synthesis, enzyme activities, DNA repair capacities, hormonal
action, glucose intolerance, and behavior and learning (Sohal and
Weindruch, 1996; Wachsman, 1996; Yu, 1996). Not surprisingly, there
are a number of competing (and not necessarily exclusive) hypotheses
concerning the possible mechanisms underlying the anti-aging and
anti-cancer effects of CR. The preliminary finding that CR exerts
similar beneficial effects on some biomarkers of aging in nonhuman
primates (Lane et al, 1996, 1997; Ramsey et al, 1997) suggests that a
better understanding of CR in rodents may ultimately translate to
practicable interventions in human populations.
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were restricted to 60% of the average calorie intake
of the respective ad libitum group, however, only 33%
developed such lesions, and the CR mice survived twice
as long on average as the ad libitum mice. CR also
extended life span in p53F/– mice, but 50% of p53F/–
mice subjected to CR still developed skin ulcers and
mean life span was shorter than that seen in WT mice.
Differences in response to CR between WT and p53F/–
mice may be due to the reduction in p53 gene dosage,
dissimilarity in the application of the CR treatment, or
both. These results suggest that some of the beneficial
effects of CR may need full expression of p53 for complete
realization. Key words: carcinogenesis/gene dosage/gluco-
corticoids/immune system. J Invest Dermatol 111:292–296, 1998
We have previously shown that the nullizygous p53-deficient mouse
provides a useful model for cancer prevention studies, because lack of
the p53 tumor suppressor gene product results in tumor development
that is rapid and spontaneous (Donehower et al, 1992) and yet capable
of modulation by dietary and chemopreventive interventions, including
CR (Hursting, 1997). We have demonstrated that the tumor-delaying
effects of CR on the spontaneous neoplasms (primarily hematopoietic
neoplasms and sarcomas) that these mice develop are independent of
p53 (Hursting et al, 1997). The heterozygous p53-deficient (p531/–)
mouse, with its similarities to the familial cancer-prone Li–Fraumeni
syndrome in humans and its increased susceptibility to a variety of
carcinogens (Donehower, 1996), promises to be a useful model of
cancer predisposition that will also be suitable for cancer prevention
studies. Indeed, we are finding that CR and other interventions are
effective against spontaneous tumorigenesis in this model as well
(unpublished data).
The mouse multistage skin carcinogenesis model has proven to be
a very powerful tool in the elucidation of the genetic and epigenetic
factors that lead to malignancy (Slaga et al, 1995). In this system,
tumors are initiated irreversibly by the topical application of a single
low dose of carcinogen, followed by repeated treatments with a
noncarcinogenic promoter. Multiple papillomas appear after a short
latency period and are succeeded much later by squamous cell
carcinomas.
In this study, we wished to examine the effect of CR on induced
skin neoplasms in p531/– mice, in which reduction of p53 gene dosage
has been shown to result in a more rapid progression of skin papillomas
to malignancy (Kemp et al, 1993). To increase the probability of skin
neoplasms in that study, F1 and F2 hybrid offspring between p531/–
mice and highly susceptible inbred NIH stocks were used. Because
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the main background strain of our mice (C57BL/6) is highly resistant
to promotion of skin cancers by phorbol esters (Reiners et al, 1984),
we elected to use a frequent dosing schedule that has been shown to
promote a tumor response in C57BL/6 J mice (Fischer et al, 1988).
Unfortunately, however, this treatment protocol entails a high risk of
an acute toxic response and in this study had to be suspended. Most
of the mice in the groups fed ad libitum (AL) developed ulcerative skin
lesions and died from the subsequent infection and septicemia, with
very few skin cancers observed. Remarkably, however, mice subjected
to CR were much more resistant to the development of skin lesions,
died less frequently from infection/septicemia, and consequently lived
much longer than mice that were not on CR. Furthermore, reduction
of p53 gene dosage in p531/– mice may have diminished the beneficial
effects of CR in these circumstances.
MATERIALS AND METHODS
Animals and diets Thirty-four male p531/– mice and 35 male wild-
type (WT) litter mates (GenPharm International, Mountain View, CA) were
individually housed in polycarbonate cages on hardwood bedding and maintained
on a 12 h light:dark cycle at 24°C. The colony from which these mice were
obtained was generated from 129/Sv-, C57BL/6 chimeric founders (Donehower
et al, 1992) with back crosses to C57BL/6 J mice for two generations followed
by back crosses to NIH C57BL/6 mice for two more generations; N5 p531/–
mice were produced by an additional back cross to C57BL/6 mice. Following
a 3 wk acclimation period after receipt, during which time all mice were fed
AIN-76 A purified diet AL (BioServ, Frenchtown, NJ), p531/– and WT mice
(5–11 wk of age at receipt) were randomly assigned to one of two dietary
treatment groups (16–19 mice per group): (i) AL, which received AIN-76 A
diet AL; or (ii) CR, which received a specially modified AIN-76 A diet in
daily aliquots restricted to 60% of food consumption by the respective AL
group. As previously described (Hursting et al, 1994), the modified AIN-76 A
diet was formulated such that the reduction in calories was entirely from the
carbohydrate ingredients of the diet, with all other components isonutrient
relative to the respective AL group when consumed at 60% of the average
intake of the AL mice. Each diet was manufactured as 1 g dustless precision
pellets and administered to AL mice in weekly aliquots and to CR mice in
daily aliquots in standard feeders; weekly food consumption by an individual
AL mouse was estimated from the weight of the food remaining in the feeder,
plus that of any pieces of pellets that had fallen into the bedding. All mice
received distilled water AL. Individual food consumption and body weight
were recorded weekly.
Chemical treatments After dietary pretreatment for 8 wk, the dorsal skin
of each animal was shaved and 2 d later topically treated with a single dose of
7,12-dimethylbenz[a]anthracene (DMBA) (100 µg in 0.2 ml acetone). Beginning
1 wk later, each mouse was treated with five topical applications of 12-O-
tetradecanoylphorbol-13-acetate (TPA) (4 µg in 0.2 ml acetone) per week for
2 wk, then two applications per week for the next 8 wk; treatments were
thereupon discontinued for the duration of the study because a large number
of the mice developed ulcerative dermatitis.
Analysis All mice were observed daily for clinical signs of ill health. Moribund
mice were killed by CO2 asphyxiation. All animals that were killed or found
dead were necropsied, and their tissues were fixed and histopathologically
analyzed as previously described (Hursting et al, 1994). The degree of myeloid
hyperplasia (MH) was evaluated in the femur and/or cranium, and granulocytic
extramedullary hematopoiesis (EMH) was scored in the spleen, liver, and lymph
nodes; the most severe grade present in an individual was used for comparisons.
The survival distributions for the treatment groups were compared using the
Cox proportional hazards model (Cox, 1972); computations were performed
using the computer program developed and described by Thomas et al (1977).
Tumor multiplicities and deaths from infection/septicemia were compared
using the nonparametric Kruskal–Wallis and Wilcoxon rank-sum procedures
(Hollander and Wolfe, 1973). The χ2 test was used to compare causes of death;
pair-wise comparisons were made with the Fisher exact test (Colquhoun, 1971).
Tumor incidences were compared by the age-adjusted prevalence method
followed by the Mantel–Haenszel procedure (Peto et al, 1980). Correlations
were tested with Spearman’s rank correlation procedure; mean body weights
and food consumption were compared by the Student’s t test (InStat for
Macintosh vs. 2.03, GraphPad Software, San Diego, CA). Reported probabilities
are two-tailed.
RESULTS
Frequent chemical treatment causes skin ulceration The pur-
pose of this study was to compare in p531/– mice and WT mice the
Figure 1. CR reduces mean body weight. CR (open symbols) at 60% of
average AL intake reduced weekly mean body weights of p531/– mice (j)
and WT mice (d) prior to DMBA injection, but had a lesser effect subsequently
because of increased food intake by AL-fed mice (filled symbols). All mice began
diet treatment (AL or CR) 8 wk prior to a single dose of DMBA applied
topically (arrow). Diet treatments were continued, and topical TPA application
was begun 1 wk after DMBA administration and continued for 10 wk, at
which time it was discontinued due to the high incidence of ulcerative
dermatitis. Monthly values (mean 6 SD) are plotted; *, points at which the
mean body weight of CR p531/– mice was significantly greater than that of
CR WT mice (p , 0.05).
effects of CR on the well-characterized skin model of multistage
carcinogenesis; however, only two mice developed skin tumors, with
one squamous cell carcinoma observed in each AL group. TPA
treatments were prematurely stopped because many of the animals
developed (at the site of chemical application) severe skin lesions that
failed to heal, even with no further TPA treatment; as a result, instead
of skin carcinomas the majority of the mice died of complications
ensuing from the toxicity of the treatment protocol. These skin lesions
developed more quickly (in 2–5 wk of TPA treatment) than skin
neoplasms would have been expected to appear (Fischer et al, 1988).
When the chemical treatments were initiated, the steady increase in
body weight seen in AL-fed mice stalled and never resumed (Fig 1),
despite significantly increased food consumption by these mice (data
not shown). Among the mice fed AL, 89% died of infection/septicemia
(Table I). The AL-fed groups of mice died at the same rate, regardless
of p53 genotype (Fig 2); mean times to death were 220 and 212 d
for p531/– and WT mice, respectively.
CR reduces infection-related mortality As in our previous studies
(Hursting et al, 1994, 1997), CR at 60% of AL intake markedly
reduced mean body weights, compared with AL-fed groups of mice,
at least during the first part of the study (Fig 1). In contrast to other
studies in which this CR protocol resulted in little or no increase in
mean body weight for the duration of the study (Hursting et al, 1994;
Perkins et al, in preparation), CR mice gained weight at later time
points. Because the amount of food provided to the CR mice is
calculated from the average AL intake (see Materials and Methods), this
weight gain was directly related to the significant and atypical increase
in food consumption by the AL groups that occurred after chemical
treatments were initiated (weekly food intake increased 40–45% by
week 20 on study, data not shown). As a result, mean body weights
of the CR groups increased when average food consumption by the
respective AL groups increased with the development of skin lesions
(Fig 1). Furthermore, despite equivalent average food consumption
by p531/– and WT mice before chemical treatments, by 6 wk into
the study CR p531/– mice weighed significantly more than WT CR
mice (p ø 0.028). At 20 and 30 wk into the study AL p531/– mice
consumed µ10% more food than AL WT mice (data not shown);
therefore, CR p531/– mice also consumed proportionally more than
CR WT mice. The difference in food consumption between p531/–
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Table I. Effect of CR on cause of death and types of
neoplasms in DMBA/TPA-treated heterozygous p53-deficient
and WT mice
p531/– WT
AL CR AL CR
(n 5 16) (n 5 18) (n 5 19) (n 5 16)
Cause of death (%)
Infection/septicemia 88 50g 89 31h
Neoplasma 12 39 5 62
Otherb/undetermined 0 11 5 6
Neoplasmsa (no.)
Mice with neoplasms 4 8 5 11
Mice with multiple neoplasms 0 3 1 5
Types:
Hematopoietic neoplasmsc 1 5 1 10
Sarcomasd 2 4 0 2
Other malignanciese 1 2 2 5
Benign neoplasmsf 0 1 3 0
aNo differences when data are age adjusted for different group survival times.
bUrinary stasis; cystic pancreatic duct.
cHistiocytic sarcoma; lymphoblastic lymphoma; follicular center cell lymphoma.
dHemangiosarcoma; fibrosarcoma; osteosarcoma.
eSquamous cell carcinoma; hepatocellular carcinoma; alveolar carcinoma; olfactory
neuroblastoma.
fHepatocellular adenoma; alveolar adenoma; pituitary adenoma.
gDifferent from respective AL group, p 5 0.030.
hDifferent from respective AL group, p 5 0.0006.
and WT mice was not statistically different (p 5 0.086 for 20 wk and
p 5 0.216 for 30 wk), but may be related to differences in the severity
of the skin lesions (see below). Although they were provided only
60% of the calories consumed by the AL-fed mice, by 23 wk of the
study the CR p531/– mice did not weigh significantly less than AL
p531/– mice (p ù 0.172) (Fig 1). The same was true for CR and AL
WT mice by 31 wk of the study (p ù 0.088).
Despite the fact that the degree of dietary restriction in the later
stages of the study was less than intended, CR nevertheless had striking
effects on cause of death and time to death in these mice, regardless
of p53 status (Table I, Fig 2). In p531/– mice, CR reduced the
proportion of deaths from infection/septicemia from 88 to 50% (p 5
0.030) (Table I) and substantially increased the life span relative to
p531/– mice fed AL, with a mean time to death of 339 d compared
with 220 d for the AL-fed group (p 5 0.0002) (Fig 2). In CR WT
mice only 31% of deaths were attributed to infection/septicemia (p 5
0.0006 compared with 89% of deaths in AL WT group) (Table I) and
the mean time to death increased to 419 d, compared with 212 d for
the respective AL group (p 5 0.0044). CR WT mice lived significantly
longer than CR p531/– mice (p 5 0.040) (Fig 2). Among the
subgroups of mice that died of infection/septicemia, CR increased
mean time to death from 204 to 338 d for p531/– mice (p 5 0.0028)
and from 203 to 419 d for WT mice (p 5 0.0151) (data not shown).
Time to death from infection/septicemia did not differ statistically
between CR p531/– mice and CR WT mice (p 5 0.35).
For the mice that did not die of infection/septicemia, neoplasms
were the most common cause of death (Table I). The mix of
lymphomas, histiocytic sarcomas, and nonhistiocytic sarcomas was
similar to what we have previously observed in p531/– mice (Hursting
et al in preparation; Perkins et al in preparation) and WT mice (Hursting
et al, 1997), except that no liver neoplasms were noted in the WT
mice in this study. For neoplasm-related deaths in CR mice, p531/–
and WT mice died at the same rates by the Cox proportional hazards
model (mean times to death 378 and 454 d, respectively, p 5 0.41;
data not shown). Compared with the respective AL groups, more
hematopoietic neoplasms were observed in CR p531/– and WT mice
(Table I); however, age adjustment of the data to compensate for the
different mean survival times indicated that the increase in incidence
of hematopoietic neoplasms among the CR mice was simply associated
with their longer survival. The average time to death for CR WT
mice that died of malignant neoplasms of all types (454 d) was less
Figure 2. CR increases life span in p531/– and WT mice. p531/– mice
(j) and WT mice (d) were fed AL (filled symbols) or CR (open symbols) to
60% of average AL intake. All mice began diet treatment (AL or CR) 8 wk
prior to a single dose of DMBA applied topically (arrow). Diet treatments
were continued, and topical TPA application was begun 1 wk after DMBA
administration and continued for 10 wk, at which time it was discontinued
due to the high incidence of ulcerative dermatitis. p531/– and WT mice fed
AL died at the same rate (p 5 0.94). Compared with the respective AL group,
CR increased the life span of both p531/– mice (p 5 0.0002) and WT mice
(p 5 0.0044).
Figure 3. CR prevents skin ulceration at the site of application of
DMBA and TPA. (a) Normal skin from WT mouse subjected to CR;
(b) ulcerated skin from p531/– mouse fed AL. Scale bar, 130 µm.
than the 646 d we saw previously in CR WT mice that were not
subjected to chemical treatments and died from spontaneous neoplasms
(Hursting et al, 1997). Thus, while the abbreviated DMBA/TPA
regimen induced neither skin papillomas nor carcinomas in appreciable
numbers, it nevertheless appeared to hasten death from hematopoietic
neoplasms and sarcomas in CR WT mice.
Reduced p53 gene dosage may lessen beneficial responses to
CR In contrast to our previous finding that the tumor-delaying
effects of CR are independent of p53 (Hursting et al, 1997), in this
study p53 status appeared to modulate the beneficial effects of CR.
CR p531/– mice died significantly sooner than CR WT mice (p 5
0.040); however, as described above, in the latter part of the study the
p531/– mice may have been subjected to a lesser degree of dietary
restriction than the WT mice, and this reduction in treatment stringency
may account for part or all of the differences in responses to CR.
As noted above, TPA treatments were halted because more than
60% of the mice developed skin ulcerations at the site of chemical
application. These lesions developed rapidly and generally did not heal,
even after TPA application was stopped. The presence of such lesions
correlated strongly with death caused by infection/septicemia (r 5
0.814, 95% confidence interval 5 0.711–0.882, p , 0.0001). When
histopathologically examined at the conclusion of the study, the skin
lesions were characterized by full thickness ulceration of the epidermis
with infiltration of admixed inflammatory cells (neutrophils, lympho-
cytes, and macrophages) into the underlying dermis and subcutis
(Fig 3). The systemic reaction consisted of reactive lymph nodes
exhibiting lymphoid hyperplasia, plasmacytosis, and EMH. Granulo-
cyctic EMH was also prominent in the spleen and liver, and the bone
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Table II. Effect of CR on skin ulceration and elevated
systemic hematopoiesis as indicated by increased MH and/or
EMH in DMBA/TPA-treated heterozygous p53-deficient and
WT micea
p531/– WT
AL CR AL CR
(n 5 15) (n 5 17) (n 5 19) (n 5 15)
Skin lesionb (%) 100 53d 74 33e
MH/EMHc (%)
none 0 0 0 20
grades 1 and 2 0 0 0 20
grades 3 and 4 100 100 100 60d
aAnimals for which autolysis precluded analysis were excluded.
bSkin ulcer (always accompanied by some degree of acanthosis and/or inflammation)
present at the site of chemical application at the time of death.
cReaction graded as minimal to mild (grades 1 and 2) or moderate to severe (grades 3
and 4).
dDifferent from respective AL group, p , 0.01.
eDifferent from respective AL group, p , 0.05.
marrow frequently showed marked granulocytic MH. Among the mice
that were fed AL, all p531/– mice developed such skin lesions, whereas
the incidence appeared lower in the WT mice (Table II) (p 5 0.053).
Compared with AL feeding, CR in both groups significantly reduced
the number of mice bearing chemically induced skin ulcers (Table II;
p 5 0.0029 for p531/– mice and p 5 0.036 for WT mice). CR also
reduced the proportion of WT mice exhibiting moderate-to-severe
grades of MH/EMH (p 5 0.0037), but all p531/– mice exhibited
elevated systemic hematopoiesis regardless of dietary treatment
(Table II).
DISCUSSION
A striking finding of this study was the dramatic increase in mean life
span induced by CR in mice that had been subjected to toxic chemical
skin treatments. Because fewer CR mice developed persistent skin
ulcers (Table II), fewer died from infection/septicemia (Table I).
These results are consistent with the emerging recognition of the
potent anti-inflammatory effects of CR in the face of a pathologic
inflammatory response; such effects are distinct from the well-known
retardation by CR of the age-dependent declines observed in most
tests of immune competence (Weindruch and Walford, 1988; Spear-
Hartley and Sherman, 1994). CR elevates corticosterone levels in mice
(Klebanov et al, 1995) and rats (Sabatino et al, 1991; Leakey et al,
1994), and has been shown to attenuate inflammation (as evaluated by
carrageenan foot pad edema) (Klebanov et al, 1995) and to have
protective activity in an acute inflammatory lung model (Kari et al,
1997). These observations support the hypothesis that CR, by elevating
levels of plasma glucocorticoids and thereby diminishing the inflam-
matory reaction, protects against the pathologic effects of overinflam-
mation (Klebanov et al, 1995); they also reinforce the view that a
physiologic role of glucocorticoids is modulation of defense mechanisms
(such as the inflammatory response) that might otherwise overshoot
and threaten homeostasis (Munck et al, 1984).
Repeated doses of TPA appear to promote skin carcinomas by
causing a chronic state of irritation and regenerative hyperplasia
(reviewed in DiGiovanni, 1992). Anti-inflammatory steroids are
extremely active inhibitors of the skin tumor-promoting effects of
phorbol esters; the most potent synthetic steroids can completely
suppress TPA-induced skin hyperplasia and epidermal DNA synthesis
(Slaga, 1980). A role for adrenal steroids in the anti-tumorigenic
activity of CR is strongly supported by reports that adrenalectomy
completely reverses the inhibition by CR of mouse skin tumor
promotion by TPA (Pashko and Schwartz, 1992) and of DMBA-
induced lung tumorigenesis in A/J mice (Pashko and Schwartz, 1996).
In this study, circulating glucocorticoids elevated by CR may have
blunted the intense inflammatory reaction to frequent TPA application
and thus may have been responsible for the suppression of skin ulcer
development and for the consequently improved life expectancy seen
in mice on the CR regimen. These results suggest that CR might be
useful therapeutically in reducing the exaggerated hyperinflammatory
response seen in some pathologic conditions.
CR significantly extended mean life span in both groups of mice,
compared with mice fed AL, but CR p531/– mice died significantly
sooner than CR WT mice (Fig 2). Compared with WT mice, in
p531/– mice CR was less effective in preventing development of skin
ulcers and death from infection/septicemia (Tables I, II); furthermore,
even in the absence of frank ulceration at the time of death, all CR
p531/– mice exhibited significantly increased myeloid hyperplasia and/
or extramedullary hematopoiesis (Table II). In contrast to our findings
with respect to CR and tumor development, in which the mechanism
underlying the CR-induced delay of neoplastic death appears to be
independent of p53 gene status (Hursting et al, 1997), this study
suggests that there may be a subtle p53 gene dosage effect in the
immune response to CR, with the result that in p531/– mice CR is
less effective in curtailing the hyperinflammatory reaction than in WT
mice. As noted in the Results, however, the average body weight of
the CR p531/– mice was significantly greater than that of the CR
WT mice for much of the study (Fig 1). This observation raises the
possibility that the different responses to CR may reflect different
levels of dietary restriction in the p531/– and WT mice, rather than
solely or even primarily as a result of p53 gene status.
Murine p53 gene dosage effects have been noted in a number of
pathologic states, among them frequency of neural tube defects
(Armstrong et al, 1995; Sah et al, 1995), teratogen susceptibility (Nicol
et al, 1995), and induction of O6-alkylguanine-DNA-alkyltransferase
in response to ionizing radiation (Rafferty et al, 1996). p531/– mice
develop fewer lymphomas (and more sarcomas) than nullizygous p53-
deficient mice, and the average latency for all neoplasms, although
accelerated compared with WT mice, is longer than in nullizygous
p53-deficient mice (Harvey et al, 1993b; Jacks et al 1994; Purdie et al,
1994). Although loss of the remaining WT p53 allele has been observed
in roughly half of tumors that develop in p531/– mice, loss of
heterozygosity at the p53 locus is clearly not required for tumor
formation; these and other observations suggest that reduction of p53
gene dosage in itself may be sufficient to increase susceptibility to
cancer (Donehower, 1996).
That the p53 gene product plays a role in immune development
and response is suggested by the remarkable susceptibility of nullizygous
p53-deficient mice to lymphoma (regardless of mouse strain back-
ground) (Harvey et al, 1993a; Donehower et al, 1995), and by
the defective B-cell maturation (Shick et al, 1997) and increased
predisposition to infectious disease (Donehower et al, 1992) observed
in these mice. A possible mechanism that would link p53 status and
the immune system is suggested by our observations that in vitro
induction of nitric oxide synthase II (NOS2) activity in freshly isolated
peritoneal macrophages is lower in ex vivo cells from nullizygous p53-
deficient mice compared with those from WT mice (Mei et al, in
press), and that the amount of NOS2 activity induced in p531/–
embryonic fibroblasts is intermediate between nullizygous p53-deficient
and WT embryonic fibroblasts (Mei et al, unpublished data). Given
that generation of nitric oxide appears to be a critical component of
the anti-microbial mechanisms rallied to defend against infection
(MacMicking et al, 1997), diminished capacity to do so because of
reduced p53 gene dosage may ultimately be responsible for the increased
susceptibility to infection noted in nullizygous p53-deficient mice
(Donehower et al, 1992) and in p531/– mice (this study). Although
WT p53 has been shown to repress NOS2 expression at the level of
the NOS2 promoter (Forrester et al, 1996), our data suggest that
resultant NOS2 expression depends on integration of control at
multiple levels.
In summary, CR markedly reduced the incidence of skin lesions
and death from infection/septicemia (and thus consequently increased
mean life span) in mice that had been subjected to ulcerating topical
application of TPA. The reduction of p53 gene dosage in p531/– mice
may have reduced the salutary activity of CR in this context; this
finding suggests that some of the beneficial effects of CR may need
full expression of p53 for complete realization.
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